Literature DB >> 17909018

A CDKN2A mutation in familial melanoma that abrogates binding of p16INK4a to CDK4 but not CDK6.

Rebecca Jones1, Margarida Ruas, Fiona Gregory, Stephanie Moulin, Domenico Delia, Siranoush Manoukian, Janice Rowe, Sharon Brookes, Gordon Peters.   

Abstract

The CDKN2A locus encodes two distinct proteins, p16INK4a and p14ARF, both of which are implicated in replicative senescence and tumor suppression in different contexts. Here, we describe the characterization of a novel strain of human diploid fibroblasts (designated Milan HDFs) from an individual who is homozygous for the R24P mutation in p16INK4a. As this mutation occurs in the first exon of INK4a (exon 1alpha), it has no effect on the primary sequence of p14(ARF). Based on both in vitro and in vivo analyses, the R24P variant is specifically defective for binding to CDK4 but remains able to associate with CDK6. Nevertheless, Milan HDFs behave as if they are p16INK4a deficient, in terms of sensitivity to spontaneous and oncogene-induced senescence, and the R24P variant has little effect on proliferation when ectopically expressed in normal fibroblasts. It can, however, impair the proliferation of U20S cells, presumably because they express more CDK6 than primary fibroblasts. These observations suggest that CDK4 and CDK6 are not functionally redundant and underscore the importance of CDK4 in the development of melanoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17909018     DOI: 10.1158/0008-5472.CAN-07-1528

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

Review 1.  Pathways of oncogene-induced senescence in human melanocytic cells.

Authors:  Rajat Bansal; Mikhail A Nikiforov
Journal:  Cell Cycle       Date:  2010-07-03       Impact factor: 4.534

2.  Kinase requirements in human cells: II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells.

Authors:  Amy Baldwin; Wenliang Li; Miranda Grace; Joseph Pearlberg; Ed Harlow; Karl Münger; Dorre A Grueneberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-23       Impact factor: 11.205

Review 3.  Molecular pathology of cutaneous melanoma.

Authors:  Léon C van Kempen; Margaret Redpath; Caroline Robert; Alan Spatz
Journal:  Melanoma Manag       Date:  2014-12-04

4.  The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence.

Authors:  Sebastian Haferkamp; Sieu L Tran; Therese M Becker; Lyndee L Scurr; Richard F Kefford; Helen Rizos
Journal:  Aging (Albany NY)       Date:  2009-05-16       Impact factor: 5.682

5.  MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL.

Authors:  Marieke H van der Linden; Merel Willekes; Eddy van Roon; Lidija Seslija; Pauline Schneider; Rob Pieters; Ronald W Stam
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

6.  Predicting the functional impact of protein mutations: application to cancer genomics.

Authors:  Boris Reva; Yevgeniy Antipin; Chris Sander
Journal:  Nucleic Acids Res       Date:  2011-07-03       Impact factor: 16.971

7.  Cyclin-dependent kinase 6 phosphorylates NF-κB P65 at serine 536 and contributes to the regulation of inflammatory gene expression.

Authors:  Holger Buss; Katja Handschick; Nadine Jurrmann; Pirita Pekkonen; Knut Beuerlein; Helmut Müller; Robin Wait; Jeremy Saklatvala; Päivi M Ojala; M Lienhard Schmitz; Michael Naumann; Michael Kracht
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

8.  Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions.

Authors:  Noah C Jenkins; Jae Jung; Tong Liu; Megan Wilde; Sheri L Holmen; Douglas Grossman
Journal:  J Invest Dermatol       Date:  2012-11-29       Impact factor: 8.551

9.  Analyzing effects of naturally occurring missense mutations.

Authors:  Zhe Zhang; Maria A Miteva; Lin Wang; Emil Alexov
Journal:  Comput Math Methods Med       Date:  2012-04-22       Impact factor: 2.238

10.  p16INK4a-induced senescence is disabled by melanoma-associated mutations.

Authors:  Sebastian Haferkamp; Therese M Becker; Lyndee L Scurr; Richard F Kefford; Helen Rizos
Journal:  Aging Cell       Date:  2008-10       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.